Thu, Apr. 23, 5:39 PM
Fri, Mar. 6, 5:42 PM
Mon, Feb. 23, 12:44 PM
Mon, Feb. 23, 9:21 AM
- Bristol-Myers Squibb (NYSE:BMY) enters into a collaboration agreement with Rigal Pharmaceuticals (NASDAQ:RIGL) to discover, develop and commercialize cancer immunotherapies based on Rigal's small molecule TGF beta receptor kinase inhibitors. The partnership will focus on developing immunotherapeutics as monotherapy or in combination with immune checkpoint inhibitors, including BMY's Opdivo (nivolumab) and Yervoy (ipilimumab).
- Under the terms of the agreement, BMY will have global rights to develop and commercialize small molecule therapeutics derived from Rigal's TGF beta library, including, but not limited to, those approved to treat cancer. Rigal will receive an upfront payment of $30M, potential milestones of more than $309M for a successful compound that is cleared for multiple indications and tiered royalties on net sales.
- Transforming growth factor (TGF) beta is a secreted protein that controls proliferation, differentiation and other functions in most cells. In the immune system, it plays an immunosuppressive role which can significantly dampen anti-tumor immune responses.
- RIGL is up 42% premarket on robust volume.
Mon, Feb. 23, 9:14 AM
Aug. 13, 2014, 5:36 PM
Aug. 13, 2014, 12:46 PM
Aug. 13, 2014, 9:15 AM
Aug. 13, 2014, 8:32 AM
- Rigel Pharmaceuticals' (NASDAQ:RIGL) ophthalmic JAK/SYK inhibitor, R348, did not achieve its primary or secondary endpoints in a Phase 2 clinical trial in patients with dry eye disease. The endpoints were: changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo.
- The company will cease its development of R348 for dry eye disease but will continue its Phase 2 study of dry eye in patients with graft vs host disease (GvHD).
- Separately, the firm has stopped it indirect AMPK activator program, R118, due to its side-effect profile demonstrated in Phase 1. It will continue its direct AMPK activator research program.
- Shares are down 9% premarket on modest volume.
Mar. 6, 2014, 9:15 AM
- Gainers: PXLW +38%. BORN +30%. SGMO +17%. ERII +14%. BSPM +14%. ORAN +10%. BSDM +9%. GEVO +9%. LJPC +8%. ROX +8%. RIGL +8%. RGSE +8%. NEON +8%. PPHM +7%. NAVB +7%. FREE +6%. PSTI +6%. MVIS +5%. LOGI +5%. GRO +5%.
- Losers: LOV -20%. XGTI -13%. PLCE -12%. SPLS -11%. BLDP -8%. FCEL -6%. DANG -6%. MXWL -6%.
Mar. 4, 2014, 10:14 AM
- Shares of Rigel Pharmaceuticals (RIGL +5.7%) get a pop after reporting earnings this morning.
- Quick assets totaled $212M at years end. The company expects to burn $80M this year.
- Cash on hand is sufficient to fund operations through the second quarter of 2016.
- Mutual fund ownership has retreated from 246 to 184 over the past four quarters.
- Earnings release
Oct. 24, 2013, 11:12 AM
- Rigel Pharmaceuticals (RIGL -1.4%) gives investors a pipeline update.
- R333 is out (at least as a potential treatment for active skin lesions in DLE patients) after the drug missed its primary endpoint in a Phase 2 study.
- RIGL will initiate two pivotal studies of fostamatinib for ITP in H1 2014. Investors should expect top line data in 2015. (PR)
Aug. 26, 2013, 12:45 PM| Comment!
Aug. 26, 2013, 12:39 PM
- Rigel Pharmaceuticals (RIGL -12.1%) sells off sharply after the company announces disappointing results from a Phase 2 study of R343 in allergic asthma.
- Leerink however, maintains an Outperform rating on the shares, saying expectations for the remaining near-term catalysts are low.
- Price target lowered to $5 from $7.
Aug. 26, 2013, 9:11 AM
Jun. 4, 2013, 9:11 AM
RIGL vs. ETF Alternatives
Rigel Pharmaceuticals Inc is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
Other News & PR